1. Medtech Insight
  2. >>Archive

Arthroscopy for the Weekend Warrior

According to "US Markets for Arthroscopy Products," a recent report from Windhover/Medtech Insight that discusses in great detail the markets and products relating to the minimally invasive repair of injuries to the joints, there were more than 4 million arthroscopy procedures on the knees and shoulders in 2005. Overall, the US arthroscopy products market is worth over $640 million and it's projected to grow at an annual rate of approximately almost 5% to reach almost $1 billion in 2010.

There's only one problem with the philosophy "Work hard, play hard." In alternating between a sedentary desk job and slaloming down a ski slope or a fast-paced game of tennis, modern man is prone to knee and shoulder injuries. Sports injuries are on the rise, as is the kind of joint degeneration that comes with long-term use, for example, degeneration of the meniscus of the knee in runners or in the elderly. According to US Markets for Arthroscopy Products, a recent report from Windhover/Medtech Insight that discusses in great detail the markets and products relating to the minimally invasive repair of injuries to the joints, there were 4.2 million arthroscopy procedures on the knees and shoulders in 2005. Overall, the US arthroscopy products market is worth over $640 million and it's projected to grow at an annual rate of almost 5% to reach approximately $1 billion in 2010.

According to the Medtech Insight report, there are almost two million diagnoses of knee injuries each year, and one million interventions, the most common being the arthroscopic repair of a...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.